| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000045 | Autophagosome assembly | Increases phenotype | PMID:25412314 |
| GO:0000080 | Mitotic g1 phase | Increases phenotype | PMID:25412314 |
| GO:0000084 | Mitotic s phase | Decreases phenotype | PMID:25412314 |
| GO:0001649 | Osteoblast differentiation | Increases phenotype | PMID:28975700 |
| GO:0002027 | Regulation of heart rate | Affects phenotype | PMID:17055290 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:35762198 |
| GO:0003056 | Regulation of vascular associated smooth muscle contraction | Increases phenotype | PMID:24449418 |
| GO:0004035 | Alkaline phosphatase activity | Increases phenotype | PMID:28975700 |
| GO:0004111 | Creatine kinase activity | Increases phenotype | PMID:33034787 |
| GO:0004602 | Glutathione peroxidase activity | Affects phenotype | PMID:27111380 |
| GO:0004679 | Amp-activated protein kinase activity | Increases phenotype | PMID:25412314 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:27111380; PMID:30342015; PMID:30408459; PMID:35762198 |
| GO:0006007 | Glucose catabolic process | Decreases phenotype | PMID:26616219 |
| GO:0006123 | Mitochondrial electron transport, cytochrome c to oxygen | Decreases phenotype | PMID:30859212 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:15488325; PMID:16325779; PMID:16470222; PMID:20427495 |
| GO:0006629 | Lipid metabolic process | Affects phenotype | PMID:35156134 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:33383043; PMID:39536891; PMID:33596472 |
| GO:0006695 | Cholesterol biosynthetic process | Affects phenotype | PMID:24613879; PMID:28734741; PMID:34890705 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:29071762; PMID:30513525; PMID:35762198 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:30408459 |
| GO:0006754 | Atp biosynthetic process | Decreases phenotype | PMID:25300705; PMID:27734117 |
| GO:0006809 | Nitric oxide biosynthetic process | Affects phenotype | PMID:25517390; PMID:30342015 |
| GO:0006811 | Monoatomic ion transport | Decreases phenotype | PMID:20644009 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:35156134 |
| GO:0006914 | Autophagy | Increases phenotype | PMID:25412314 |
| GO:0006915 | Apoptotic process | Affects phenotype | PMID:10733934; PMID:11868908; PMID:11877052; PMID:12962723; PMID:14527821; PMID:15041742; PMID:15380679; PMID:15488325; PMID:15949312; PMID:16325779; PMID:16470222; PMID:16698853; PMID:16740276; PMID:16917207; PMID:17125918; PMID:17125918; PMID:18031796; PMID:17277159; PMID:17716606; PMID:18031796; PMID:18203325; PMID:18337644; PMID:18489904; PMID:18679777; PMID:18841289; PMID:18521906; PMID:18625202; PMID:18679777; PMID:18826357; PMID:19298698; PMID:19343037; PMID:19741129; PMID:19771181; PMID:19816600; PMID:19932975; PMID:20044596; PMID:20045437; PMID:20427495; PMID:20452610; PMID:20499237; PMID:20846454; PMID:20878096; PMID:20883752; PMID:21334995; PMID:25300705 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:33774062; PMID:39536891 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:27734117 |
| GO:0006979 | Response to oxidative stress | Affects phenotype | PMID:15380679; PMID:18608208; PMID:20045437; PMID:20883752 |
| GO:0007049 | Cell cycle | Decreases phenotype | PMID:17125918; PMID:17125918; PMID:18608208; PMID:17928568; PMID:18337644; PMID:18625202; PMID:18804536; PMID:18824851; PMID:20878096; PMID:7834630 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:24449418 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:21735455; PMID:33383043; PMID:39536891; PMID:33596472; PMID:39536891 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:33383043 |
| GO:0008217 | Regulation of blood pressure | Increases phenotype | PMID:15184351; PMID:16405447; PMID:16698853; PMID:19633453 |
| GO:0008219 | Cell death | Affects phenotype | PMID:18929563; PMID:19932975; PMID:20433776; PMID:24518598; PMID:27734117; PMID:7834630; PMID:8611662; PMID:9070296 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:10412745; PMID:9808088; PMID:10733934; PMID:11877052; PMID:11877052; PMID:18824851; PMID:15160275; PMID:15488325; PMID:7834630; PMID:15705602; PMID:16470222; PMID:18199328; PMID:18203325; PMID:18489904; PMID:18608208; PMID:18625202; PMID:18804536; PMID:20644009; PMID:20878096; PMID:24613879; PMID:21109955; PMID:21334995; PMID:24524197; PMID:24613879; PMID:7834630 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:21735455; PMID:21735455; PMID:23668785; PMID:23668785; PMID:26577051; PMID:29969672; PMID:30513525; PMID:32668280; PMID:8216498 |
| GO:0008610 | Lipid biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:0008654 | Phospholipid biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:24964743; PMID:25578243 |
| GO:0010989 | Negative regulation of low-density lipoprotein particle clearance | Increases phenotype | PMID:29071762 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:27111380; PMID:30342015; PMID:30408459; PMID:35762198 |
| GO:0016049 | Cell growth | Affects phenotype | PMID:30426164 |
| GO:0017086 | 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) complex | Affects phenotype | PMID:25193403 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:27111380 |
| GO:0018342 | Protein prenylation | Decreases phenotype | PMID:27377765 |
| GO:0018344 | Protein geranylgeranylation | Decreases phenotype | PMID:37956312 |
| GO:0019216 | Regulation of lipid metabolic process | Affects phenotype | PMID:33262480 |
| GO:0019722 | Calcium-mediated signaling | Increases phenotype | PMID:14527821 |
| GO:0030154 | Cell differentiation | Affects phenotype | PMID:19109527; PMID:8611662 |
| GO:0030282 | Bone mineralization | Increases phenotype | PMID:28975700 |
| GO:0030595 | Leukocyte chemotaxis | Affects phenotype | PMID:10412745; PMID:9808088; PMID:15781755; PMID:21330348 |
| GO:0031532 | Actin cytoskeleton reorganization | Increases phenotype | PMID:21257924 |
| GO:0032412 | Regulation of monoatomic ion transmembrane transporter activity | Decreases phenotype | PMID:20644009 |
| GO:0032930 | Positive regulation of superoxide anion generation | Increases phenotype | PMID:26773838 |
| GO:0034380 | High-density lipoprotein particle assembly | Decreases phenotype | PMID:29071762 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:29071762; PMID:30513525 |
| GO:0036438 | Maintenance of lens transparency | Affects phenotype | PMID:34890705 |
| GO:0042307 | Positive regulation of protein import into nucleus | Increases phenotype | PMID:26773838 |
| GO:0042311 | Vasodilation | Increases phenotype | PMID:12883323; PMID:16290053; PMID:20018286 |
| GO:0042632 | Cholesterol homeostasis | Decreases phenotype | PMID:29071762 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:24449418; PMID:26773838 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:25412314; PMID:31311324; PMID:37956312 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:29071762 |
| GO:0045541 | Negative regulation of cholesterol biosynthetic process | Increases phenotype | PMID:23386644; PMID:8216498 |
| GO:0045793 | Positive regulation of cell size | Decreases phenotype | PMID:21124329 |
| GO:0045795 | Positive regulation of cell volume | Increases phenotype | PMID:39536891 |
| GO:0045907 | Positive regulation of vasoconstriction | Increases phenotype | PMID:24449418 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Affects phenotype | PMID:25412314 |
| GO:0046466 | Membrane lipid catabolic process | Increases phenotype | PMID:20185263 |
| GO:0046620 | Regulation of organ growth | Increases phenotype | PMID:12883323 |
| GO:0046890 | Regulation of lipid biosynthetic process | Affects phenotype | PMID:21735455 |
| GO:0050901 | Leukocyte tethering or rolling | Increases phenotype | PMID:12379581 |
| GO:0051726 | Regulation of cell cycle | Increases phenotype | PMID:26577051 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Decreases phenotype | PMID:16325779; PMID:18679777; PMID:20045437; PMID:25300705; PMID:30859212 |
| GO:0051900 | Regulation of mitochondrial depolarization | Affects phenotype | PMID:30859212 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:30426164 |
| GO:0060612 | Adipose tissue development | Increases phenotype | PMID:10496339 |
| GO:0061577 | Calcium ion transmembrane transport via high voltage-gated calcium channel | Increases phenotype | PMID:30859212 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:25412314; PMID:35762198 |
| GO:0070328 | Triglyceride homeostasis | Decreases phenotype | PMID:29071762 |
| GO:0070994 | Detection of oxidative stress | Affects phenotype | PMID:24486436 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:35156134 |
| GO:0072672 | Neutrophil extravasation | Decreases phenotype | PMID:21330348 |
| GO:0090494 | Dopamine uptake | Affects phenotype | PMID:30769001 |
| GO:0097342 | Ripoptosome | Increases phenotype | PMID:25412314 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:39536891 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:30513525 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Affects phenotype | PMID:30426164 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:30513525 |
| GO:1990138 | Neuron projection extension | Decreases phenotype | PMID:30769001 |
| GO:2000541 | Positive regulation of protein geranylgeranylation | Decreases phenotype | PMID:25578243 |
| GO:2000774 | Positive regulation of cellular senescence | Increases phenotype | PMID:26773838 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.